NeuroPace Strengthens Management Team with Two Key Appointments
September 04, 2024 16:05 ET
|
NeuroPace, Inc.
Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific’s DBS franchise as the new Vice...
NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences
August 27, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it...
NeuroPace to Participate in Upcoming Healthcare Conferences in September
August 22, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it...
NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
August 13, 2024 16:05 ET
|
NeuroPace, Inc.
-- Revenue grew to $19.3 million in Q2 2024, a 17% increase over Q2 2023 -- -- Increased full-year 2024 revenue guidance to $76 million to $78 million -- -- Demonstrated continued operating...
NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024
July 23, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it...
NeuroPace to Participate in Two Healthcare Conferences in May
May 14, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it...
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
April 17, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced...
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
March 05, 2024 16:05 ET
|
NeuroPace, Inc.
-- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 -- -- Revenue increased to $65.4 million in 2023, a 44% increase over 2022 -- -- Provides full-year 2024 revenue...
NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
December 21, 2023 07:07 ET
|
NeuroPace, Inc.
NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy Neuromodulation therapy is not currently...
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023 16:30 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...